Red @RedReversion

Dreaming of early retirement. Joined August 2020

Tweets

3K
Followers

239
Following

54
Likes

9K

Red @RedReversion

4 weeks ago

Back above £1 incoming. Even then the price doesn't reflect the progress. #AVCT

0 0 17 979 0

@MylesMcNulty @avacta There is no way (imo) that Heights & Zeus signed up to #AVCT terms without some form of reassurance of pre|CISION performance in TNBC. Due diligence will have been undertaken. Personally believe the importance of the deal will be reflected in SP next week once people catch on 🫶🏻

1 3 40 2K 1

Sean Dent @SeanDentBsc

4 weeks ago

#AVCT have disposed of their only current revenue stream, so effectively have zero income. Yet heights have allowed us to defer our quarterly payments by over a year! 🤯 Not because we can't pay it, because as proven twice now we have the financial power of RH & Zeus behind us…

Sean Dent @SeanDentBsc

4 weeks ago

2 2 29 4K 1

1 6 46 2K 0

Highly Geared @HighlyGeared

4 weeks ago

#AVCT #Avacta #Hughes4Chair Richard Hughes fingerprints are all over this RNS! At last a commercial RNS from Avacta which cuts 3 years of CLN financial shackles, allowing the CEO and the scientific team to progress Avacta’s global oncology IP. There’s no stopping the science…

0 11 51 1K 1

Jenkoo @Jenkoool

4 weeks ago

If you are confident of near term catalysts to send the SP significantly north…. Defer bond payments to aid cash flow and reduce dilution upon payback to protect share holders. Finally we have financially astute people leading #avct forward alongside the incredible science. 🌟

0 6 53 1K 0

Carlo Towl @Towlie1981

4 weeks ago

Absolutely stellar RNS! pre|CISION being used as insurance for finance. Confidence in it (and the subsequent flow of deal making) must be off the charts for Heights to agree! #AVCT

Avacta @avacta

4 weeks ago

Absolutely stellar RNS! pre|CISION being used as insurance for finance. Confidence in it (and the subsequent flow of deal making) must be off the charts for Heights to agree! #AVCT

6 21 137 41K 1

0 4 54 1K 0

RAH @RAH00084

4 weeks ago

#AVCT Listen to the clinicians

1 14 77 8K 4

Download Video

RAH @RAH00084

2 months ago

@111BEN_111 #AVCT Nothing to see here Ben. Just the medical community calling for a solution to exact problem preCISION & FAP-EXd solves. pmc.ncbi.nlm.nih.gov/articles/PMC10… Credit: RC

1 7 57 3K 0

Download Image

Ben @111BEN_111

a year ago

PROOF This time last year I wouldn’t have imagined phase 1A #AVA6000 could yield such results #AACR24 That poster isn’t about AVA6000, it is about proving the platform With the right warhead, #AVCT could have keytruda 2.0

2 6 59 11K 0

Download Image

Highly Geared @HighlyGeared

2 months ago

Monster volume again today in #AVCT, on news that they will be presenting at a conference. It's hard to imagine the volume that will be triggered by a BP licence deal validating Avacta's IP across their platform. To borrow Doug Casey's expression, it'll be like trying to push…

0 2 46 2K 0

Christina Coughlin @coughlin582

2 months ago

Looking forward to October in Germany - cue up the data from the FAP-Dox dose escalation trial, including the longer term follow up data. Key data for the pre|CISION platform #AVCT Silent in the bloodstream. Active in the tumor.

Avacta @avacta

2 months ago

0 21 195 40K 1

Download Video

14 44 320 37K 5

Beer & 64 Bits @ZosoGraffiti

2 months ago

@Jenkoool @RAH00084 @hughesy0707 @coughlin582 Zippo. Peel should have found a home for the HC share ages ago,as should stifel before them. They are not interested, only in fees and earning from capital raises. In the bin they must go

1 1 16 389 0

Richard Hughes @hughesy0707

2 months ago

Delighted to have assisted the team at Avacta. Thanks to the team at Zeus and our quality CEO. David Bryant will add considerable value on the commercial side Now the fun begins 🧨🥳#AVCT

24 33 345 46K 1

stonks @JStonker

3 months ago

Compare and contrast #AVCT

1 8 51 2K 0

Download Image

asininityandbeyond @asininitybeyond

3 months ago

@tom_the_bomb__ @avacta Eli Lilly Oncology President + CMO have stated that if a cancer drug program needs a mid-stage trial (P2), it’s not for Lilly “If it doesn’t shrink tumors in a durable way in Phase 1, it’s not a drug in our eyes.” Think about what #AVCT has seen in SGC with A6K.1/5

1 3 37 8K 1

Avacta @avacta

3 months ago

Avacta announces a new partial response observed in a patient with salivary gland cancer in the dose expansion phase of the FAP-Dox (AVA6000) Phase 1b trial. avacta.com/new-response-i… #AVCT

4 28 166 36K 3

⛏🅾️Ⓜ️💣 @tom_the_bomb__

4 months ago

@noodles993 @AndrewDigby3 @matthewjshelley Yes, typically not done until the buyer has finished buying. So no TR1 RNS could be a good thing.

1 1 3 588 0

⛏🅾️Ⓜ️💣 @tom_the_bomb__

4 months ago

@JakeLoughlin3 Something is close. #AVCT

1 1 22 9K 1

Download Video

Mark Mitchell @emily1katie

4 months ago

I don’t pretend to understand AIM but I’m surprised people appear surprised that adding the man who is responsible for a third of all monies raised on AIM to the board of a public company (for the first time in his 35 year career) is going to result in confidence. #AVCT